Eye injury, inflammatory diseases, and exposure to toxic chemicals such as pesticides and acids used in manufacturing processes are some of the major causes of uveitis. Anterior uveitis is an inflammation of the middle part of the eye, which further includes the other vital part responsible for the vision such as iris, ciliary body, and other adjacent tissues.
The global uveitis treatment market is estimated to account for US$ 648.4 Mn in terms of value in 2020 and is expected to reach US$ 1,036.0 Mn by the end of 2027.
Global Uveitis Treatment Market: Drivers
Positive outcomes in clinical trials are expected to propel growth of the global uveitis treatment over the forecast period. For instance, in June 2019, Alimera Sciences, Inc. announced three-year follow-up data from the Phase 3 clinical trial for ILUVIEN 190 micrograms intravitreal implant in applicator, for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
Global Uveitis Treatment Market: Opportunities
R&D in uveitis is expected to offer lucrative growth opportunities for players in the global uveitis treatment over the forecast period. For instance, in May 2020, researchers from National Cheng Kung University, Taiwan, identified a novel role of reactive oxygen species in the pathogenesis of experimental autoimmune uveitis and suggested a potential antioxidant role for the treatment of autoimmune uveitis in the future.
Global Uveitis Treatment Market: Restraints
Insufficient funding for R&D in eye health is expected to hinder growth of the market. For instance, according to Peter McCluskey, Professor of Clinical Ophthalmology and Eye Health, and Director of Save Sight Institute at the Faculty of Medicine and Health at the University of Sydney, (as reported to MI Vision, an ophthalmic journal, in July 2019), research grants from the National Health and Medical Research Council (Australia) are down from 30% to around 7%.
The global uveitis treatment market was valued at US$ 605.7 Mn in 2019 and is forecast to reach a value of US$ 1,036.0 Mn by 2027 at a CAGR of 6.9% between 2020 and 2027. Major factor driving the growth of global uveitis treatment market during the forecast period include high prevalence of uveitis, and number of treatment options.
Corticosteroids held dominant position in the global uveitis treatment market in 2019, accounting for 21.1% share in terms of value, followed by Monoclonal Antibodies and Antibiotics, respectively. Corticosteroids are a primary treatment options for treating uveitis, and can be administered via multiple routes such as topical, and oral.
The market is witnessing virtual conferences due to Covid-19. For instance, in June 2020, EyePoint Pharmaceuticals, Inc. presented at the Jefferies Virtual Healthcare Conference.
Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in March 2020, Clearside Biomedical, Inc. partnered with Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, under which Arctic Vision will get an exclusive license for the commercialization and development of XIPERE (triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis) in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.
Global Uveitis Treatment Market: Competitive Landscape
Major players operating in the global uveitis treatment market include, Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.
Global Uveitis Treatment Market: Key Developments
April 2020: Alimera Sciences, Inc. reported that international net revenue increased 23% to approximately US$ 7.5 million in Q1 2020, compared to approximately US$ 6.1 million for the same period during 2019, owing to growth in the company’s DME business in direct markets and the launches of ILUVIEN’s uveitis indication in Germany and the U.K. in the second half of 2019.
April 2020: Clearside Biomedical, Inc. and Bausch Health amended and revised their partnership for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis), under which Bausch + Lomb has been granted exclusive options for the right to commercialize and develop XIPERE in Europe and the U.K., Australia and New Zealand, and South America and Mexico.